Swedish Orphan Biovitrum AB (publ)'s latest marketcap:
As of 07/05/2025, Swedish Orphan Biovitrum AB (publ)'s market capitalization has reached $10.34 B. According to our data, Swedish Orphan Biovitrum AB (publ) is the 1906th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.34 B |
| Revenue (ttm) | 2.76 B |
| Net Income (ttm) | 416.44 M |
| Shares Out | 0 |
| EPS (ttm) | 1.2 |
| Forward PE | 20.04 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/16/2025 |
Swedish Orphan Biovitrum AB (publ)'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | £10.34 B | -4.39% | 1906 |
| 12/30/2024 | £7.89 B | 11.73% | 1732 |
| 12/29/2023 | £7.06 B | 38.86% | 1772 |
| 12/30/2022 | £5.08 B | 13.6% | 2254 |
| 12/30/2021 | £4.47 B | 3.12% | 2748 |
| 12/30/2020 | £4.34 B | 16.93% | 2483 |
| 12/30/2019 | £3.71 B | -18.92% | 2409 |
| 12/28/2018 | £4.58 B | 67.56% | 1781 |
| 12/29/2017 | £2.73 B | 6.76% | 2959 |
| 12/30/2016 | £2.56 B | -11.12% | 2799 |
Company Profile
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) is an integrated biotechnology company specializing in the research, development, manufacturing, and sale of pharmaceuticals. The company focuses on therapeutic areas such as haematology, immunology, and specialty care, serving markets across Europe, North America, the Middle East, Asia, and Australia.
Business Segments
- Haematology
- Immunology
- Specialty Care
Key Products
- Alprolix – For haemophilia B
- Aspaveli®/Empaveli – Treats paroxysmal nocturnal haemoglobinuria
- Doptelet – For thrombocytopenia
- Elocta – For haemophilia A
- Gamifant – Treats hemophagocytic lymphohistiocytosis (HLH)
- VONJO – For myelofibrosis treatment
- Zynlonta – Targets aggressive malignant diseases
- Kineret – For cryopyrin-associated periodic syndrome and Still's disease
- Orfadin – Treats hereditary tyrosinaemia type-1
- Synagis – For serious lower respiratory tract infections
Additional Offerings
The company also provides other pharmaceutical products, including:
- Akynzeo
- Tegsedi
- Jyseleca
- Kepivance
- Aloxi
- Waylivra
Research & Development
Swedish Orphan Biovitrum is actively involved in developing drug substances such as:
- ReFacto AF/Xyntha – Developed for Pfizer
- BIVV001 – For haemophilia A
- Nirsevimab – Targeting respiratory syncytial virus
Strategic Collaborations
The company has established partnerships with leading organizations, including:
- Sanofi
- Apellis Pharmaceuticals Inc.
- ADC Therapeutics SA
- Cartesian Therapeutics, Inc.
Founded: 1939
Headquarters: Solna, Sweden
Frequently Asked Questions
-
What is Swedish Orphan Biovitrum AB (publ)'s (LON-0MTD) current market cap?As of 07/05/2025, Swedish Orphan Biovitrum AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $10.34 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Swedish Orphan Biovitrum AB (publ) (LON-0MTD) rank globally by market cap?Swedish Orphan Biovitrum AB (publ) global market capitalization ranking is approximately 1906 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.